{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:06:27Z","timestamp":1790154387910,"version":"4.0.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13024-015-0033-8","type":"journal-article","created":{"date-parts":[[2015,9,3]],"date-time":"2015-09-03T10:21:00Z","timestamp":1441275660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-\u03b2 and neuroinflammation in APP transgenic mice"],"prefix":"10.1186","volume":"10","author":[{"given":"Ulf","family":"Neumann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinrich","family":"Rueeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Machauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siem Jacob","family":"Veenstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer M.","family":"Lueoend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Tintelnot-Blomley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grit","family":"Laue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Beltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Vogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried","family":"Frieauff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya R.","family":"Shimshek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Staufenbiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura H.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,3]]},"reference":[{"key":"33_CR1","doi-asserted-by":"crossref","first-page":"a006262","DOI":"10.1101\/cshperspect.a006262","volume":"2","author":"CL Masters","year":"2012","unstructured":"Masters CL, Selkoe DJ. Biochemistry of amyloid \u03b2-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006262.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"33_CR2","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370:322\u201333.","journal-title":"N Engl J Med"},{"key":"33_CR3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Alzheimer\u2019s disease cooperative study steering committee; Solanezumab study group phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370:311\u201321.","journal-title":"N Engl J Med"},{"key":"33_CR4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3233\/JAD-141506","volume":"44","author":"J Wang","year":"2015","unstructured":"Wang J, Tan L, Wang HF, Tan CC, Meng XF, Wang C, et al. Anti-inflammatory drugs and risk of Alzheimer\u2019s disease: an updated systematic review and meta-analysis. J Alz Dis. 2015;44:385\u201396.","journal-title":"J Alz Dis"},{"key":"33_CR5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol. 2013;12:357\u201367.","journal-title":"Lancet Neurol"},{"key":"33_CR6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jnc.12715","volume":"130","author":"R Vassar","year":"2014","unstructured":"Vassar R, Kuhn PH, Haass C, Kennedy ME, Rajendran L, Wong PC, et al. Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J Neurochem. 2014;130:4\u201328.","journal-title":"J Neurochem"},{"key":"33_CR7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1474-4422(13)70276-X","volume":"13","author":"R Yan","year":"2014","unstructured":"Yan R, Vassar R. Targeting the \u03b2 secretase BACE1 for Alzheimer\u2019s disease therapy. Lancet Neurol. 2014;13:319\u201329.","journal-title":"Lancet Neurol"},{"key":"33_CR8","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.bmcl.2014.03.025","volume":"24","author":"D Oehlrich","year":"2014","unstructured":"Oehlrich D, Prokopcova H, Gijsen HJM. The evolution of amidine-based brain penetrant BACE1 inhibitors. Bioorg Med Chem Lett. 2014;24:2033\u201345.","journal-title":"Bioorg Med Chem Lett"},{"key":"33_CR9","doi-asserted-by":"crossref","first-page":"9346","DOI":"10.1021\/jm3009025","volume":"55","author":"B-M Swahn","year":"2012","unstructured":"Swahn B-M, Kolmodin K, Karlstr\u00f6m S, von Berg S, S\u00f6derman P, Holenz J, et al. Design and Synthesis of \u03b2-Site Amyloid predursor Protein Cleaving enzyme (BACE1) inhibitors with in vivo Brain reduction of \u03b2-Amyloid Peptides. J Med Chem. 2012;55:9346\u201361.","journal-title":"J Med Chem"},{"key":"33_CR10","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1523\/JNEUROSCI.4129-14.2015","volume":"35","author":"PC May","year":"2015","unstructured":"May PC, Willis BA, Lowe SL, Dean RA, Monk SA, Cocke PJ, et al. The potent BACE1 inhibitor LY2886721 elicits robust central A\u03b2 pharmacodynamic responses in mice, dogs, and humans. J Neurosci. 2015;35:1199\u2013210.","journal-title":"J Neurosci"},{"key":"33_CR11","doi-asserted-by":"crossref","first-page":"16507","DOI":"10.1523\/JNEUROSCI.3647-11.2011","volume":"31","author":"PC May","year":"2011","unstructured":"May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, et al. Robust central reduction of amyloid-\u03b2 in humans with an orally available, non-peptidic \u03b2-secretase inhibitor. J Neurosci. 2011;31:16507\u201316.","journal-title":"J Neurosci"},{"key":"33_CR12","doi-asserted-by":"crossref","unstructured":"Fielden MR, Werner J, Jamison JA, Coppi A, Hickman D, Dunn RT, et al. Retinal toxicity induced by a novel \u03b2-secretase inhibitor in the sprague-dawley rat. Toxicol Pathol. 2015;43:581\u201392.","DOI":"10.1177\/0192623314553804"},{"key":"33_CR13","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1021\/jm970530e","volume":"41","author":"M Kansy","year":"1998","unstructured":"Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeability assay in the description of passive absorption processes. J Med Chem. 1998;41:1007\u201310.","journal-title":"J Med Chem"},{"key":"33_CR14","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1124\/dmd.107.017434","volume":"36","author":"B Feng","year":"2008","unstructured":"Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, et al. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos. 2008;36:268\u201375.","journal-title":"Drug Metab Dispos"},{"key":"33_CR15","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.bbadis.2013.03.016","volume":"1832","author":"E Head","year":"2013","unstructured":"Head E. A canine model of human aging and Alzheimer\u2019s disease. Biochim Biophys Acta. 2013;1832:1384\u20139.","journal-title":"Biochim Biophys Acta"},{"key":"33_CR16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000341217","volume":"12","author":"Y Lu","year":"2013","unstructured":"Lu Y, Barton HA, Leung L, Zhang L, Hajos-Korcsok E, Nolan CE, et al. Cerebrospinal fluid \u03b2-Amyloid turnover in the mouse, dog, monkey and human evaluated by systematic quantitative analyses. Neurodeg Dis. 2013;12:36\u201350.","journal-title":"Neurodeg Dis"},{"key":"33_CR17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1471-4159.2011.07412.x","volume":"119","author":"S Rabe","year":"2011","unstructured":"Rabe S, Reichwald J, Ammaturo D, de Strooper B, Saftig P, Neumann U, et al. The Swedish APP mutation alters the effect of genetically reduced BACE1 expression on the APP processing. J Neurochem. 2011;119:231\u20139.","journal-title":"J Neurochem"},{"key":"33_CR18","doi-asserted-by":"crossref","first-page":"26326","DOI":"10.1074\/jbc.M611687200","volume":"282","author":"L McConlogue","year":"2007","unstructured":"McConlogue L, Buttini M, Anderson JP, Brigham EF, Chen KS, Freedman SB, et al. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. J Biol Chem. 2007;282:26326\u201334.","journal-title":"J Biol Chem"},{"key":"33_CR19","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1074\/jbc.M109.066753","volume":"285","author":"H Yamakawa","year":"2010","unstructured":"Yamakawa H, Yagishita S, Futai E, Ishiura S. \u03b2-Secretase inhibitor potency is decreased by aberrant \u03b2-cleavage location of the \u201cSwedish Mutant\u201d amyloid precursor protein. J Biol Chem. 2010;285:1634\u201342.","journal-title":"J Biol Chem"},{"key":"33_CR20","doi-asserted-by":"crossref","first-page":"6931","DOI":"10.1523\/JNEUROSCI.2262-14.2015","volume":"35","author":"DR Thakker","year":"2015","unstructured":"Thakker DR, Sankaranarayanan S, Weatherspoon MR, Harrison J, Pierdomenico M, Heisel JM, et al. Centrally delivered BACE1 inhibitor activates microglia, and reverses amyloid pathology and cognitive deficit in aged Tg2576 mice. J Neurosc. 2015;35:6931\u20136.","journal-title":"J Neurosc"},{"key":"33_CR21","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1124\/jpet.108.140327","volume":"327","author":"D Abramowski","year":"2008","unstructured":"Abramowski D, Wiederhold KH, Furrer U, Jaton AL, Neuenschwander A, Runser MJ, et al. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J Pharmacol Exp Ther. 2008;327:411\u201324.","journal-title":"J Pharmacol Exp Ther"},{"key":"33_CR22","doi-asserted-by":"crossref","first-page":"11621","DOI":"10.1523\/JNEUROSCI.1405-14.2014","volume":"34","author":"H Jacobsen","year":"2014","unstructured":"Jacobsen H, Ozmen L, Caruso A, Narquizian R, Hilpert H, Jacobsen B, et al. Combined treatment with a BACE inhibitor and anti-A\u03b2 antibody gantenerumab enhances amyloid reduction in APPLondon mice. J Neurosci. 2014;34:11621\u201330.","journal-title":"J Neurosci"},{"key":"33_CR23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3109\/00207454.2013.831852","volume":"124","author":"M Obulesu","year":"2014","unstructured":"Obulesu M, Jhansilakshimi M. Neuroinflammation in Alzheimer\u2019s disease: an understanding of physiology and pathology. Int J Neurosci. 2014;124:227\u201335.","journal-title":"Int J Neurosci"},{"key":"33_CR24","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.brainresrev.2009.11.004","volume":"63","author":"MT Heneka","year":"2010","unstructured":"Heneka MT, Rodrigues JJ, Verkhratsky A. Neuroglia in neurodegeneration. Brain Res Rev. 2010;63:189\u2013211.","journal-title":"Brain Res Rev"},{"key":"33_CR25","doi-asserted-by":"crossref","unstructured":"Latta CH, Brothers HM, Wilcock DM. Neuroinflammation in Alzheimer\u2019s disease; a source of heterogeneity and target for personalized therapy. Neuroscience, ahead of print. doi: 10.1016\/j.neuroscience.2014.09.061 .","DOI":"10.1016\/j.neuroscience.2014.09.061"},{"key":"33_CR26","doi-asserted-by":"crossref","first-page":"10658","DOI":"10.1073\/pnas.1220748110","volume":"110","author":"L Rochin","year":"2013","unstructured":"Rochin L, Hurbain I, Serneels L, Fort C, Watt B, Leblanc P, et al. BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells. Proc Natl Acad Sci USA. 2013;110:10658\u201363.","journal-title":"Proc Natl Acad Sci USA"},{"key":"33_CR27","doi-asserted-by":"crossref","first-page":"a006346","DOI":"10.1101\/cshperspect.a006346","volume":"2","author":"T Wyss-Coray","year":"2012","unstructured":"Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med. 2012;2:a006346.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"33_CR28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science. 2002;297:253\u20136.","journal-title":"Science"},{"key":"33_CR29","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1021\/jm001020e","volume":"44","author":"F Wohnsland","year":"2001","unstructured":"Wohnsland F, Faller B. High-throughput permeability pH profile and high-throughput alkane\/water log P with artificial membranes. J Med Chem. 2001;44:923\u201330.","journal-title":"J Med Chem"},{"key":"33_CR30","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1021\/jm070375w","volume":"50","author":"H Wan","year":"2007","unstructured":"Wan H, Rehngren M, Giordanetto F, Bergstr\u00f6m F, Tunek A. High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. J Med Chem. 2007;50:4606\u201315.","journal-title":"J Med Chem"},{"key":"33_CR31","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/nn1302","volume":"7","author":"MC Herzig","year":"2004","unstructured":"Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, et al. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nature Neurosci. 2004;7:954\u201360.","journal-title":"Nature Neurosci"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-015-0033-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:35:05Z","timestamp":1567125305000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.molecularneurodegeneration.com\/content\/10\/1\/44"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,3]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["33"],"URL":"https:\/\/doi.org\/10.1186\/s13024-015-0033-8","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,3]]},"article-number":"44"}}